Cargando…

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids

There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD), for which there are no approved drugs today. Here, we used a human in vitro disease model to understand mechanisms linked to genetic risk variants associated with NAFLD. The model is based on 3D sphero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prill, Sebastian, Caddeo, Andrea, Baselli, Guido, Jamialahmadi, Oveis, Dongiovanni, Paola, Rametta, Raffaela, Kanebratt, Kajsa P., Pujia, Arturo, Pingitore, Piero, Mancina, Rosellina Margherita, Lindén, Daniel, Whatling, Carl, Janefeldt, Annika, Kozyra, Mikael, Ingelman-Sundberg, Magnus, Valenti, Luca, Andersson, Tommy B., Romeo, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690969/ https://www.ncbi.nlm.nih.gov/pubmed/31406127 http://dx.doi.org/10.1038/s41598-019-47737-w

Ejemplares similares

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
por: Borén, Jan, et al.
Publicado: (2020)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
por: Baselli, Guido Alessandro, et al.
Publicado: (2020)

PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis
por: Pingitore, Piero, et al.
Publicado: (2016)

The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant
por: Zhang, Xiaoyu, et al.
Publicado: (2018)

PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
por: Pirazzi, Carlo, et al.
Publicado: (2014)

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
por: Dongiovanni, Paola, et al.
Publicado: (2018)

Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2
por: Fan, Yanbo, et al.
Publicado: (2021)

From Environment to Genome and Back: A Lesson from HFE Mutations
por: Rametta, Raffaela, et al.
Publicado: (2020)

The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism
por: Chen, Lizhen, et al.
Publicado: (2017)

TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease
por: Chen, Li-Zhen, et al.
Publicado: (2015)

E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
por: Du, Shuixian, et al.
Publicado: (2017)

Genetic and Epigenetic Modifiers of Alcoholic Liver Disease
por: Meroni, Marica, et al.
Publicado: (2018)

The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis
por: Liu, Zhengtao, et al.
Publicado: (2017)

TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6
por: Du, Shuixian, et al.
Publicado: (2019)

Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes
por: Sookoian, Silvia, et al.
Publicado: (2016)

Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance
por: Rahim, Nur Syafiqah, et al.
Publicado: (2023)

Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma
por: Chen, Zhouxun, et al.
Publicado: (2011)

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
por: Donati, Benedetta, et al.
Publicado: (2017)

Targeting TM4SF5 with anti-TM4SF5 monoclonal antibody suppresses the growth and motility of human pancreatic cancer cells
por: Park, Sangkyu, et al.
Publicado: (2020)

Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis
por: Zhu, Wenzhen, et al.
Publicado: (2022)

LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover
por: Tanaka, Yuki, et al.
Publicado: (2021)

Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity
por: Ahn, Hye-Mi, et al.
Publicado: (2017)

Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease
por: Wu, Jian-Ting, et al.
Publicado: (2020)

TM4SF5-Mediated Roles in the Development of Fibrotic Phenotypes
por: Ryu, Jihye, et al.
Publicado: (2017)

Human hepatic 3D spheroids as a model for steatosis and insulin resistance
por: Kozyra, Mikael, et al.
Publicado: (2018)

PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes
por: Mancina, Rosellina Margherita, et al.
Publicado: (2015)

PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC
por: Kruk, Beata, et al.
Publicado: (2018)

TM4SF5-mediated protein-protein networks and tumorigenic roles
por: Lee, Jung Weon
Publicado: (2014)

The loss of Tm7sf gene accelerates skin papilloma formation in mice
por: Bellezza, I., et al.
Publicado: (2015)

Amino acid transporters as tetraspanin TM4SF5 binding partners
por: Jung, Jae Woo, et al.
Publicado: (2020)

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
por: Meroni, Marica, et al.
Publicado: (2020)

N-terminus-independent activation of c-Src via binding to a tetraspan(in) TM4SF5 in hepatocellular carcinoma is abolished by the TM4SF5 C-terminal peptide application
por: Song, Haeng Eun, et al.
Publicado: (2021)

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
por: Dongiovanni, Paola, et al.
Publicado: (2010)

TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo
por: Cao, Jia, et al.
Publicado: (2015)

TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth
por: Singhal, Megha, et al.
Publicado: (2019)

TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis
por: Basyte-Bacevice, Viktorija, et al.
Publicado: (2019)

TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype
por: Sagnelli, Caterina, et al.
Publicado: (2016)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
por: Longo, Miriam, et al.
Publicado: (2021)

Use of Hall 167
por: Jacob, U
Publicado: (1981)

PSD3 downregulation confers protection against fatty liver disease
por: Mancina, Rosellina M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_etkemmu7muth6fh6vs641gsv3k